A new analysis charts how rAAV dose costs vary by indication and estimates capacity needs across six leading gene therapy targets, including RPE65 retinal dystrophy, AMD, hemophilia A and B, SMA, and Duchenne muscular dystrophy. The study uses prevalence-based patient estimates and indication-specific dose assumptions to identify where manufacturing bottlenecks may concentrate. The findings are intended to support planning for both providers and manufacturers as rAAV expands into a broader set of clinical indications. By focusing on cost and capacity differences rather than a one-size estimate, the work highlights which programs may face the steepest scaling pressure. — Key takeaway: indication-level economics are increasingly central to feasibility discussions for AAV expansion.